Related Experiment Videos
Thymoma. A retrospective study of 87 cases
1Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Cancer
|May 15, 1994
Summary
Chemotherapy, particularly cisplatin-based regimens, shows a survival benefit for malignant thymoma patients, especially those with advanced or recurrent disease. Incorporating chemotherapy into multimodality treatment can improve disease-free survival.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- Retrospective analysis of 87 malignant thymoma patients treated between 1951 and 1990.
- Examined clinical stages, histology, and treatment modalities to assess chemotherapy's impact on survival.
Purpose of the Study:
- To determine the impact of chemotherapy on survival rates in malignant thymoma patients.
- To evaluate the effectiveness of different chemotherapy regimens over time.
Main Methods:
- Patients grouped by treatment era (1951-1975, 1976-1980, 1981-1990).
- Treatment modalities included surgery, radiotherapy, and various chemotherapy regimens (single-agent, combination, cisplatin/doxorubicin-based).
- Survival analysis of patients receiving cisplatin with or without prednisone.
Main Results:
- Chemotherapy was administered to 28 patients, with higher rates in later treatment groups.
- Cisplatin-based regimens showed a 64% overall response rate (35% complete, 29% partial).
- Survival rates varied by stage, with significant differences observed between Stage I, Stage II/III, and Stage IV disease. Major response to cisplatin regimen correlated with improved survival (P=0.002).
Conclusions:
- Malignant thymoma is a chemosensitive tumor with a potential survival benefit from chemotherapy.
- Chemotherapy should be integrated into multimodality treatment for Stage II or greater disease to prolong disease-free survival.
- Recurrence is common, particularly in the lung, pleura, and mediastinum.